Healthcare -
Biotechnology - NASDAQ - US
$ 2.58
7.05 %
$ 24.6 M
Market Cap
-2.1
P/E
1. INTRINSIC VALUE
Balance Sheet
NeurAxis, Inc.
| Current Assets | 4.27 M |
| Cash & Short-Term Investments | 3.7 M |
| Receivables | 245 K |
| Other Current Assets | 325 K |
| Non-Current Assets | 491 K |
| Long-Term Investments | 0 |
| PP&E | 375 K |
| Other Non-Current Assets | 117 K |
| Current Liabilities | 2.43 M |
| Accounts Payable | 597 K |
| Short-Term Debt | 217 K |
| Other Current Liabilities | 1.62 M |
| Non-Current Liabilities | 256 K |
| Long-Term Debt | 256 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
NeurAxis, Inc.
| Revenue | 2.69 M |
| Cost Of Revenue | 362 K |
| Gross Profit | 2.32 M |
| Operating Expenses | 9.48 M |
| Operating Income | -7.16 M |
| Other Expenses | 1.08 M |
| Net Income | -8.24 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NeurAxis, Inc.
| Net Income | -8.24 M |
| Depreciation & Amortization | 37.8 K |
| Capital Expenditures | -27.8 K |
| Stock-Based Compensation | 1.4 M |
| Change in Working Capital | 0 |
| Others | 701 K |
| Free Cash Flow | -6.13 M |
Wall Street Analysts Price Targets
NeurAxis, Inc.
Wall Street analysts predict an average 1-year price target for NRXS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
NRXS Lowest Price Target
Wall Street Target
7 USD
171.32%
NRXS Average Price Target
Wall Street Target
7 USD
171.32%
NRXS Highest Price Target
Wall Street Target
7 USD
171.32%
4. DIVIDEND
ANALYSIS
NRXS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
NeurAxis, Inc.
Sold
0-3 MONTHS
652 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), covering two health insurers, with approximately 700,000 total members in Connecticut and Massachusetts. This medical policy will bring our national total coverage for PENFS to roughly 53 million, with more decisions from major payers still pending.
globenewswire.com
- 2 weeks ago
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of $3.25 per share.
globenewswire.com
- 1 month ago
NeurAxis Announces $5.0 Million Registered Direct Offering
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,538,461 shares of its common stock at a purchase price of $3.25 per share in a registered direct offering priced at the market under NYSE American rules.
globenewswire.com
- 1 month ago
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones
NRXS posts strong first-quarter 2025 earnings with robust revenue growth and FDA milestones, driving stock gains as investors eye broader insurance coverage and market expansion.
zacks.com
- 1 month ago
NeurAxis, Inc. (NRXS) Q1 2025 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q1 2025 Earnings Conference Call May 12, 2025 9:00 AM ET Company Participants Ben Shamsian - IR Brian Carrico - President, CEO & Director Tim Henrichs - CFO Brian Carrico - President, CEO & Director Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the NeurAxis First Quarter 2025 Results and Update Call.
seekingalpha.com
- 1 month ago
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.
globenewswire.com
- 1 month ago
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time
globenewswire.com
- 2 months ago
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth
NRXS records strong revenue growth, expanded insurance coverage and new FDA clearances in fourth-quarter 2024.
zacks.com
- 3 months ago
NeurAxis, Inc. (NRXS) Q4 2024 Earnings Call Transcript
NeurAxis, Inc. (NYSE:NRXS ) Q4 2024 Earnings Conference Call March 20, 2025 9:00 AM ET Company Participants Ben Shamsian - Investor Relations Brian Carrico - Chief Executive Officer Tim Henrichs - Chief Financial Officer Operator Good day, and thank you for standing by. Welcome to the NeurAxis' Fourth Quarter 2024 Financial Results Conference Call.
seekingalpha.com
- 3 months ago
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended December 31, 2024.
globenewswire.com
- 3 months ago
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its fourth quarter and fiscal year 2024, for the period ended December 31, 2024, on Thursday, March 20, 2025, before market open. The Company has scheduled a conference call for the same day, Thursday, March 20, 2025, at 9:00 am ET to review the results.
globenewswire.com
- 3 months ago
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States
CARMEL, Ind., Jan. 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), with a prominent insurer, with approximately 5.1 million members across 13 states.
globenewswire.com
- 5 months ago
8. Profile
Summary
NeurAxis, Inc. NRXS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 24.6 M
Dividend Yield
0.00%
Description
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Contact
11550 North Meridian Street, Carmel, IN, 46032
https://neuraxis.com
IPO
Date
Aug. 9, 2023
Employees
21
Officers
Mr. Timothy Robert Henrichs
Chief Financial Officer
Dr. Adrian Miranda
Senior Vice President of Science & Technology and Chief Medical Officer
Dr. Thomas Carrico
Chief Regulatory Officer and Compliance & Privacy Officer
Mr. Brian Carrico
President, Chief Executive Officer & Director
Dr. Christopher Robin Brown D.D.S.
Founder, Director of Innovation & Director